Scinai Immunotherapeutics to Lead Strategic Roundtable Discussion on Oral Therapies and the Future of Biologics at the 7th Dermatology Drug Development Summit Europe

Rhea-AI Summary

Scinai Immunotherapeutics (NASDAQ: SCNI) will lead a strategic roundtable at the 7th Dermatology Drug Development Summit Europe in Amsterdam.

The session, led by CEO Amir Reichman and Dr. Meital Portugal, will examine how oral peptides and small molecules may complement or compete with biologic therapies in immunology and dermatology.

News Market Reaction – SCNI

+0.24%

3 alerts

+0.24% Session close to close

$2.26M Market Cap

0.0x Rel. Volume

In the May 15 session, SCNI gained 0.24%, reflecting a mild positive market reaction. Our momentum scanner triggered 3 alerts that day, indicating moderate trading interest and price volatility.

Data tracked by StockTitan Argus on the day of publication.

Market Context

This announcement highlights Scinai’s role in shaping dermatology and immunology discussions via a r...

Analysis

This announcement highlights Scinai’s role in shaping dermatology and immunology discussions via a roundtable on oral therapies and biologics at the 7th Dermatology Drug Development Summit Europe. It reinforces the company’s focus on advanced biologic formats and next‑generation modalities, complementing recent CDMO expansion and pipeline efforts. Investors may watch how this visibility translates into partnerships, CDMO demand, and progress on immunology assets alongside the capital structure changes outlined in recent filings.

Key Figures

Conference edition: 7th Publication date: May 15, 2026

2 metrics

Conference edition 7th 7th Dermatology Drug Development Summit Europe

Publication date May 15, 2026 Press release announcement date

Historical Context

5 past events · Latest: Apr 24 (Neutral)

Pattern 5 events

Date	Event	Sentiment	24h Move	Catalyst
Apr 24	Private placement financing	Neutral	+61.6%	Raised $2.61M via ADSs and warrants to fund CDMO and pipeline.
Apr 06	Strategic reorganization	Positive	+1.7%	Created dedicated CDMO subsidiary and outlined 2026 revenue priorities.
Apr 01	Full-year 2025 results	Neutral	+12.1%	Reported doubled CDMO revenue and expanded Recipharm collaboration.
Mar 19	Conference participation	Neutral	-0.7%	Highlighted expanded CDMO platform and dermatology antibody pipeline.
Mar 16	Nasdaq bid notice	Negative	+0.7%	Disclosed noncompliance with Nasdaq’s $1.00 minimum bid requirement.

24h Move is the share-price change in the day after each event; other market factors may also have contributed.

Pattern Detected

Recent news has often seen positive or mixed items met with modestly positive price moves, but regulatory or compliance headlines have occasionally produced divergent reactions.

Recent Company History

Over the last six months, SCNI has combined financial restructuring with strategic repositioning. A $2.61 million private placement on April 24, 2026 supported expansion of its CDMO platform and pipeline. Earlier in April, the company completed a CDMO-focused reorganization and reported 2025 results with doubled CDMO revenues but ongoing losses. March updates highlighted its BIO-Europe Spring presence and, separately, Nasdaq minimum bid price noncompliance. Today’s dermatology roundtable role fits the ongoing emphasis on immunology visibility and CDMO-driven growth.

Key Terms

oral peptides, small molecules, biologics, cytokine blockers, +4 more

8 terms

oral peptides medical

"How Oral Peptides and Small Molecules Are Reshaping the Immunology Landscape"

Oral peptides are small chains of amino acids formulated so they can be taken by mouth and absorbed into the bloodstream instead of being injected. For investors, they matter because if a drug class usually given by injection can be made orally, it can broaden patient use, reduce treatment costs and improve adherence—potentially expanding market size—though technical challenges in stability and absorption can make development expensive and risky.

small molecules medical

"How Oral Peptides and Small Molecules Are Reshaping the Immunology Landscape"

Small molecules are compact chemical compounds, often developed as medicines, that act by fitting into and altering the behavior of biological targets like proteins — think of them as tiny keys designed to turn specific locks in the body. For investors, they matter because small-molecule drugs are usually easier and cheaper to make, store and deliver (often as pills), have well-established regulatory pathways, and can offer scalable, potentially high-return commercial opportunities if they gain approval and market acceptance.

biologics medical

"Oral Therapies and the Future of Biologics: How Oral Peptides and Small Molecules..."

Biologics are medicines made from living cells or their components rather than from simple chemical recipes, more like a handcrafted product than a mass-produced pill. They matter to investors because they often command higher prices and longer patent protection but also carry greater manufacturing, regulatory and supply risks—so a successful biologic can boost a company’s revenue significantly, while setbacks can quickly affect its stock.

cytokine blockers medical

"Whether oral cytokine blockers can achieve biologic-competitive efficacy..."

Cytokine blockers are medicines that stop or reduce signals immune cells use to call in and amplify inflammation, like cutting the phone lines that escalate a house fire. For investors, they matter because these drugs can treat a range of inflammatory and immune-related diseases, so success or safety problems in development, approval, or use can strongly affect a drug maker’s sales prospects, legal risk and valuation.

immunologic pathways medical

"Whether certain immunologic pathways may remain inherently more suitable..."

Immunologic pathways are the chains of signals and cells the immune system uses to detect threats and decide how to respond, like a series of switches and routes in a control system. Investors care because many drugs and diagnostics are designed to change specific pathways to treat disease or avoid side effects; understanding which pathway a product targets helps judge its likely effectiveness, safety profile, and commercial potential.

pharmacokinetic variability medical

"challenges associated with oral immunology therapies, including pharmacokinetic variability..."

Pharmacokinetic variability is the difference in how a drug moves through people’s bodies — how fast it is absorbed, how it spreads, how the body breaks it down, and how it leaves. Like different cars getting different miles per gallon on the same road, this variation affects how well a given dose works and how likely side effects are, so investors watch it because high variability can complicate dosing, slow regulatory approval, require extra testing or monitoring, and influence a drug’s commercial success.

bioavailability limitations medical

"oral immunology therapies, including pharmacokinetic variability, bioavailability limitations..."

When a drug or compound has trouble reaching sufficient levels in the body or target tissue after administration, those obstacles are called bioavailability limitations. For investors this matters because poor bioavailability can reduce a medicine’s effectiveness, force higher doses or expensive reformulation, delay approvals, and shrink commercial potential—like a useful tool that can’t reach the job site because the delivery truck keeps leaking.

route of administration medical

"Whether the route of administration itself may become a strategic differentiator..."

Route of administration is the method by which a drug or medical product is given to a patient — for example, by mouth, injection, inhalation, or applied to the skin. It matters to investors because the delivery method affects how quickly and reliably a therapy works, safety profiles, manufacturing and distribution complexity, and patient acceptance; think of it like a product’s shipping method, which shapes cost, convenience and market reach.

AI-generated analysis. How Rhea-AI works. Not financial advice.

See more from StockTitan in Google Search and AI answers. Adds StockTitan as a preferred source · opens Google

Add on Google Not now

JERUSALEM, May 15, 2026 /PRNewswire/ -- Scinai Immunotherapeutics Ltd. (NASDAQ: SCNI), ("Scinai" or the "Company") a biopharmaceutical company focused on inflammation and immunology, today announced that members of its leadership team will lead a strategic roundtable discussion at the 7th Dermatology Drug Development Summit Europe, taking place next week in Amsterdam, the Netherlands.

The roundtable discussion, titled "Oral Therapies and the Future of Biologics: How Oral Peptides and Small Molecules Are Reshaping the Immunology Landscape", will be led by Amir Reichman, Chief Executive Officer of Scinai Immunotherapeutics, together with Dr. Meital Portugal, Director of R&D Operations.

The discussion will focus on one of the emerging strategic questions in immunology and dermatology drug development: whether advances in oral peptide and small molecule therapies may complement biologics, reshape treatment sequencing, or meaningfully displace injectable therapies in selected disease settings.

The session will explore scientific, clinical, commercial, and strategic questions currently facing the immunology industry, including:

• Whether certain immunologic pathways may remain inherently more suitable for injectable biologics
• Whether oral cytokine blockers can achieve biologic-competitive efficacy, selectivity, and long-term durability
• Which diseases and cytokine pathways may be most vulnerable to oral therapeutic disruption
• Whether the route of administration itself may become a strategic differentiator in immunology portfolio development
• The evolving balance between efficacy, convenience, adherence, safety, persistence of response, and long-term disease control
• How oral therapies may influence treatment sequencing, physician confidence, payer dynamics, and lifecycle management strategies for biologic franchises

The roundtable will also examine key translational and clinical development challenges associated with oral immunology therapies, including pharmacokinetic variability, bioavailability limitations, treatment adherence dependence, durability of response, and sustained disease modification.

"The immunology field is entering a period of rapid evolution where scientific innovation is no longer focused solely on efficacy, but increasingly also on durability, convenience, accessibility, treatment persistence, and strategic modality selection," said Amir Reichman, Chief Executive Officer of Scinai Immunotherapeutics.

"One of the most important emerging questions for the industry is not simply whether oral therapies will grow, but rather where oral modalities may complement biologics, where they may compete directly, and which disease settings may continue to favour advanced biologic approaches. We believe these discussions are becoming increasingly important for companies developing next-generation immunology therapies."

Scinai's participation in the summit reflects the Company's broader focus on innovative immunology approaches, including advanced biologic formats, differentiated cytokine-targeting strategies, and next-generation therapeutic modalities.

The Dermatology Drug Development Summit Europe brings together biotechnology and pharmaceutical companies, translational researchers, clinicians, and industry leaders focused on the future of dermatology therapeutics and immune-mediated disease innovation.

About Scinai Immunotherapeutics

Scinai Immunotherapeutics Ltd. (NASDAQ: SCNI) is a biopharmaceutical company focused on the development of innovative immunology therapies. The Company is advancing a pipeline of therapeutic candidates licensed from the Max Planck Society and from PinCell S.r.l.

Scinai also owns Scinai Biopharma Services Ltd., a contract development and manufacturing organization (CDMO), providing development and manufacturing services to biotechnology and pharmaceutical companies.

For more information, please visit: www.scinai.com 

Company Contacts
Business Development | +972 8 930 2529 | bd@scinai.com
Investor Relations – Allele Capital Partners | +1 978 857 5075 | aeriksen@allelecapital.com

Forward-Looking Statements

This press release contains forward-looking statements within the meaning of the U.S. Private Securities Litigation Reform Act of 1995 and other applicable securities laws. Forward-looking statements include, among other things, statements regarding the Company's strategic positioning, participation in scientific and industry discussions, advancement of its immunology and inflammation pipeline, development of novel biologic and immunotherapeutic approaches, expansion of its CDMO activities, execution of business development opportunities, potential partnerships, and future industry and market trends.

These statements are based on current expectations and assumptions and are subject to risks and uncertainties that could cause actual results to differ materially from those expressed or implied by such statements. These risks and uncertainties include, without limitation, risks related to the Company's ability to advance its product candidates, secure financing or non-dilutive funding, expand its CDMO operations, integrate acquired operations, attract and retain customers and partners, execute on strategic initiatives, and general market, industry, regulatory, and economic conditions. More detailed information regarding these and other risks and uncertainties is included in the Company's filings with the U.S. Securities and Exchange Commission.

Forward-looking statements speak only as of the date of this press release. Except as required by applicable law, the Company undertakes no obligation to update or revise any forward-looking statements to reflect new information, future events, or otherwise.

Logo: https://mma.prnewswire.com/media/2310190/Scinai_Immunotherapeutics_Logo.jpg

 

View original content:https://www.prnewswire.com/news-releases/scinai-immunotherapeutics-to-lead-strategic-roundtable-discussion-on-oral-therapies-and-the-future-of-biologics-at-the-7th-dermatology-drug-development-summit-europe-302773524.html

SOURCE Scinai Immunotherapeutics Ltd.

FAQ

What will Scinai Immunotherapeutics (NASDAQ: SCNI) discuss at the 7th Dermatology Drug Development Summit Europe?

Scinai Immunotherapeutics will lead a roundtable on oral therapies and the future of biologics in immunology. According to Scinai, the session will examine scientific, clinical, commercial, and strategic questions shaping dermatology and immune-mediated disease treatment.

Who from Scinai Immunotherapeutics will lead the oral therapies roundtable at the 2026 dermatology summit?

The roundtable will be led by CEO Amir Reichman and Dr. Meital Portugal, Director of R&D Operations. According to Scinai, they will guide discussion on oral peptides, small molecules, and their relationship with injectable biologic therapies in immunology and dermatology.

What key topics will the Scinai (SCNI) roundtable on oral therapies and biologics cover?

The roundtable will cover oral peptides, small molecules, biologic-competitive efficacy, and treatment sequencing. According to Scinai, it will also address adherence, durability of response, safety, payer dynamics, and portfolio strategy in immunology and dermatology drug development.

How might oral therapies impact biologic drugs according to Scinai Immunotherapeutics?

Oral therapies may complement biologics, compete directly, or leave some settings favoring injectable biologics. According to Scinai, the discussion will explore which diseases, cytokine pathways, and administration routes could be most affected by emerging oral immunology treatments.

What development challenges for oral immunology therapies will Scinai highlight at the summit?

Scinai plans to discuss pharmacokinetic variability, bioavailability limits, adherence dependence, and durability of response. According to Scinai, the roundtable will also examine sustained disease modification and long-term control challenges for next-generation oral immunology treatments.

Why is Scinai Immunotherapeutics focusing on oral therapies and biologics in dermatology?

Scinai views immunology as shifting toward durability, convenience, accessibility, and modality selection. According to Scinai, its summit role aligns with its work on advanced biologic formats, differentiated cytokine-targeting strategies, and next-generation therapeutic modalities for immune-mediated diseases.